Elevated anti-cyclic citrullinated peptide antibodies can be lowered by taking anti-rheumatic medications prescribed by your doctor to improve your condition. Anti-cyclic citrullinated peptide antibodies are specific for rheumatoid arthritis, and elevated levels of anti-cyclic citrullinated peptide antibodies indicate that the patient may have rheumatoid arthritis. Anti-cyclic citrullinated peptide antibodies are higher than normal during periods of stable rheumatoid arthritis and can rise further when the disease is active. The current medications that can control rheumatoid arthritis are mainly disease-modifying anti-rheumatic drugs (DMARDS), which can be categorized into conventional DMARDS and biological DMARDS. Traditional DMARDS are currently the drugs of choice for rheumatoid arthritis, including methotrexate, leflunomide, hydroxychloroquine, and salazosulfapyridine. Biological DMARDS include TNF-α antagonists (e.g., infliximab), IL-1 antagonists (e.g., anabolic acid), and CD20 monoclonal antibodies (e.g., rituximab). In addition, botanical preparations such as tretinoin polyglucoside and total white peony glycosides can also be used for rheumatoid arthritis immunomodulatory therapy. When rheumatoid arthritis is under control, the level of anti-cyclic citrullinated peptide antibody will mostly decrease. It is recommended that rheumatoid arthritis patients should consult the rheumatology and immunology department in time, and standardized treatment should be carried out under the guidance of doctors.